Trastuzumab: hopes and realities (Q34569899)

3 August 2017

1 reference

title

Trastuzumab: hopes and realities (English)

1 reference

3 August 2017

1 reference

Brian Leyland-Jones

1

1 reference

3 August 2017

1 March 2002

1 reference

Lancet Oncology Commission

3 August 2017

1 reference

3 August 2017

3

1 reference

3 August 2017

3

1 reference

3 August 2017

137-144

1 reference

Treatment of breast cancer

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Monoclonal antibody therapy for solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Breast cancer therapies in development. A review of their pharmacology and clinical potential.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Toward checkmate: biology and breast cancer therapy for the new millennium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Recommendations for HER2 testing in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Mechanism of action of anti-HER2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2802%2900676-9

7 January 2021

10.1016/S1470-2045(02)00676-9

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

11902499